LY3537982 Clinical Trials
3 recruitingDrug
Phase 12Phase 21Phase 31
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company1,264 enrolled422 locationsNCT06119581
Recruiting
Phase 1
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
Renal Insufficiency
Eli Lilly and Company32 enrolled4 locationsNCT07137689
Recruiting
Phase 1Phase 2
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company540 enrolled49 locationsNCT04956640